

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Emily Bernhardt

APPLICATION NO: 09/463,097

FILED: JANUARY 18, 2000

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE  
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS  
USE

MS: 313©

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
OCT 22 2004  
OFFICE OF PETITIONS

**PETITION UNDER 37 CFR §1.313(c)(2) TO WITHDRAW APPLICATION FROM ISSUE**

Sir:

Applicant respectfully petitions for the withdrawal from issuance of the above-identified patent application. Submitted herewith is a Request for Continued Examination of the above-identified application. Applicant is petitioning for the withdrawal from issue of the present application, and is filing a Continued Prosecution Application Request , in order that an Information Disclosure Statement be considered by the U.S. Patent and Trademark Office. Applicants request consideration by the Examiner of additional references which have recently come to the attention of the undersigned attorney. Please charge the petition fee of \$130 pursuant to 37 CFR §1.17(h) to Deposit Account Number 19-0134 in the name of Novartis.

Respectfully submitted,



George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824

Date: October 21, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Emily Bernhardt

APPLICATION NO: 09/463,097

FILED: JANUARY 18, 2000

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE  
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS  
USE

MS: 313©

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
OCT 22 2004  
OFFICE OF PETITIONS

**PETITION UNDER 37 CFR §1.313(c)(2) TO WITHDRAW APPLICATION FROM ISSUE**

Sir:

Applicant respectfully petitions for the withdrawal from issuance of the above-identified patent application. Submitted herewith is a Request for Continued Examination of the above-identified application. Applicant is petitioning for the withdrawal from issue of the present application, and is filing a Continued Prosecution Application Request , in order that an Information Disclosure Statement be considered by the U.S. Patent and Trademark Office. Applicants request consideration by the Examiner of additional references which have recently come to the attention of the undersigned attorney. Please charge the petition fee of \$130 pursuant to 37 CFR §1.17(h) to Deposit Account Number 19-0134 in the name of Novartis.

Respectfully submitted,



George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824

Date: October 21, 2004